Equity research analysts and quantitative stock projection models evaluating Corcept Therapeutics (CORT) anticipate trading ranges shifting dynamically throughout the year. Financial forecasting algorithms project year-end valuation targets hovering between $97 and approximately $156 per share, depending on quarterly earnings beats, prescription sales momentum, and clinical trial updates. These estimates adjust continuously based on broader market performance and institutional investor sentiment.